[2] Zimlichman E, et. al. Health Care–Associated Infections: A Meta-analysis of Costs and Financial Impact on the US Health Care System, JAMA Intern Med. 2013;173(22):2039-2046.
[3] Chen, Donald et al. “Genomic Sequencing and Clinical Data Integration for Next-Generation Infection Prevention” Open Forum Infectious Diseases vol. 5, Suppl 1 S379–S380. 26 Nov. 2018, doi:10.1093/ofid/ofy210.1081
[4] Ellison, Richard T et al. “Utility of Routine Genomic Sequencing for Infection Control Surveillance” Open Forum Infectious Diseases vol. 4, Suppl 1 S35. 4 Oct. 2017, doi:10.1093/ofid/ofx162.086
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2018 sales of EUR 18.1 billion and employs approximately 77,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
Back to HCB News
